Searchable abstracts of presentations at key conferences in endocrinology

ea0092op-03-02 | Oral Session 3: Signalling in Thyroid cancer | ETA2023

Determination of the role of map kinase and PI3K/AKT signaling pathways in the regulation of multidrug resistance proteins in thyroid cancer

Godlewska Marlena , Ratajczak Maciej , Gajda Ewa , Gawel agata , Zebracka-Gala Jadwiga , Cieślicka Marta , Oczko-Wojciechowska Malgorzata , Kowalska Malgorzata , Gawel Damian

Thyroid cancer (TC) has one of the fastest increasing incidences worldwide and primarily involves papillary thyroid cancer (PTC). Cancer cells have numerous mechanisms that govern drug resistance, among which activation of multidrug resistance (MDR) genes encoding ABC efflux pumps plays an important role. Acquisition of drug resistance by TC cells is becoming a significant obstacle to effective therapy, leading to insensitivity to classical chemotherapeutics, but also to speci...

ea0014p369 | (1) | ECE2007

CRABP2 expression is up-regulated in parathyroid adenomas in correlation with HRPT2 down-regulation

Zebracka Jadwiga , Waler Janusz , Kowalska Malgorzata , Gala Grzegorz , Gawrychowski Jacek , Jarzab Barbara

Introduction: The molecular events involved in the formation of parathyroid adenomas are not well understood. Two genes, cyclin D1 (CCND1) and MEN-1, have been established as having major roles in parathyroid tumorigenesis. Tumor suppressor gene HRPT2 is frequently mutated in parathyroid carcinoma. The aim of our study was to analyze HRPT2 expression in parathyroid adenomas and in residual normal/atrophic parathyroid tissue and to relate it to other...

ea0035p832 | Pituitary Basic (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Correlation of coexpression of pituitary genes in QPCR and microarray study in pituitary adenomas

Zebracka-Gala Jadwiga , Larysz Dawid , Pfeifer Aleksandra , Rudnik Adam , Krajewska Jolanta , Hasse-Lazar Kornelia , Kowalska Malgorzata , Bazowski Piotr , Jarzab Barbara

Introduction: Mechanism of pathogenesis of pituitary adenomas is still unknown. Gene expression differences in pituitary cells of different origin are not extensively described. Identification of genes specific for pituitary adenomas should enable better understanding of differences in their response to therapy, especially to radiotherapy.Aim: The aim of our study was to evaluate the correlation of coexpression of distinct pituitary adenoma genes based o...

ea0035oc3.5 | Neuroendocrinology &amp; Signalling | ECE2014

NTRK3 receptor expression is strictly associated with medullary thyroid cancer RET mutation status

Oczko-Wojciechowska Malgorzata , Swierniak Michal , Kowalska Malgorzata , Pawlaczek Agnieszka , Kowal Monika , Tyszkiewicz Tomasz , Zebracka-Gala Jadwiga , Rusinek Dagmara , Gawlik Tomasz , Krajewska Jolanta

Aim of the study: Medullary thyroid cancer (MTC) occurs as hereditary and sporadic form. Hereditary type is a consequence of RET proto-oncogene germline mutations also somatic RET mutations are detectable in sporadic MTC tumors. There is a significant relation between site of mutation and the cancer phenotype as well as a clinical course of the MEN 2 Syndrome as a consequence of the different transforming potential of the RET gene mutations. The aim ...

ea0035p1103 | Thyroid Cancer | ECE2014

Single nucleotide polymorphisms associated with papillary thyroid cancer

Kula Dorota , Michal Kalemba , Daria Handkiewicz-Junak , Zbigniew Puch , Malgorzata Kowalska , Monika Kowal , Tomasz Tyszkiewicz , Renata Cyplinska , Joanna Polanska , Barbara Jarzab

Papillary thyroid cancer (PTC) is well known family occurring cancer disease. It is estimated, that ~5% of differentiated thyroid cancers (where PTC is the most frequent) are hereditary. Susceptibility genes are poorly known, however, recently some SNPs located on chromosome 9 in FOXE1 locus (rs965513) and on chromosome 14 (rs944289) close to NKX2-1 locus have been confirmed to be associated with PTC in different populations.The aim of our study was to a...

ea0035p1152 | Thyroid Cancer | ECE2014

Gene expression signature associated with BRAFV600E mutation in human papillary thyroid carcinoma based on transgenic mouse model

Rusinek Dagmara , Swierniak Michal , Chmielik Ewa , Kowal Monika , Kowalska Malgorzata , Czarniecka Agnieszka , Przeorek Cezary , Cyplinska Renata , Jarzab Michal , Widlak Wieslawa , Jarzab Barbara

Objectives: Recent studies on BRAFV600E mutation, known as initiating event in papillary thyroid carcinoma (PTC) and related to more aggressive clinical course of the disease, revealed its significant influence on gene expression profile suggesting that BRAF(+)PTCs represent a molecular subtype of PTC. However, the human material disables distinction of possible molecular causes of cancer from its effects, unlike the mouse model. The main goal of our project was to find genes ...

ea0092ps1-09-09 | Thyroid Cancer | ETA2023

A novel somatic genetic alteration in sporadic medullary thyroid carcinoma

Kowalska Malgorzata , Pfeifer Aleksandra , Zebracka-Gala Jadwiga , Cieślicka Marta , Chmielik Ewa , Rusinek Dagmara , Krajewska Jolanta , Czarniecka Agnieszka , Oczko-Wojciechowska Malgorzata

Introduction: Medullary thyroid carcinoma (MTC) is a malignant thyroid tumor originating from parafollicular C-cells. Most of MTCs (75%) are sporadic while remaining are hereditary. The hereditary form of MTC is a consequence of the mutation of the proto-oncogene RET (Rearranged During Transfection). Somatic mutations of the RET gene are also present in 40%-70% of the sporadic form of MTC (sMTC). Somatic mutations are also observed in the RAS genes and very rarely in the BRAF ...

ea0040p5 | (1) | ESEBEC2016

Mouse model of BRAFV600E-induced papillary thyroid carcinoma – summary of our results

Rusinek Dagmara , Swierniak Michal , Chmielik Ewa , Kowal Monika , Kowalska Malgorzata , Cyplinska Renata , Czarniecka Agnieszka , Piglowski Wojciech , Korfanty Joanna , Chekan Mykola , Jarzab Michal , Krajewska Jolanta , Szpak-Ulczok Sylwia , Widłak Wieslawa , Jarzab Barbara

Introduction: BRAFV600E mutation is the most frequent alteration in papillary thyroid carcinoma (PTC). Although its relation to factors of poor prognosis was demonstrated in many studies the use of BRAF as a predictive marker in clinical treatment of PTC patients is controversial. The aim of our study was to analyze molecular consequences of BRAFV600E mutation in a transgenic mouse model performed for this purpose and to refer the obtained results to...

ea0014p368 | (1) | ECE2007

Initiating mutations of BRAF gene in papillary thyroid carcinoma and their relation to gene expression profile

Rusinek Dagmara , Wiench Malgorzata , Oczko-Wojciechowska Malgorzata , Zebracka Jadwiga , Kowalska Malgorzata , Handkiewicz-Junak Daria , Szpak-Ulczok Sylwia , Chmielik Ewa , Czarniecka Agnieszka , Jarzab Michal , Gala Grzegorz , Gubala Elzbieta , Jarzab Barbara

Introduction: Discovery of V600E (BRAFT1799A) mutation in papillary thyroid carcinoma (PTC) widened our knowledge about mechanisms of its molecular initiation. It has been revealed that activating mutations of the BRAF kinase are much more frequent in PTC than RET rearrangements.Aim of the study: Estimation of V600E BRAF mutation frequency in PTC and analysis of differences in gene expression profile between papillary thyroid car...